<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969357</url>
  </required_header>
  <id_info>
    <org_study_id>HR-SP-201</org_study_id>
    <nct_id>NCT01969357</nct_id>
  </id_info>
  <brief_title>A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes</brief_title>
  <official_title>A Multicenter Randomized, Double-blind, Placebo and Positive Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the
      effective dose range of SP2086 in Patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change from baseline in HbA1c at 12 week</measure>
    <time_frame>baseline, week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Less Than (&lt;) 6.5% or &lt;7% HbA1c Levels</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 4, 8 and 12</measure>
    <time_frame>Baseline, Week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 4 ,12</measure>
    <time_frame>baseline, week 4 ,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Homeostasis model assessment-beta(HOMA-β) at week 4,week12</measure>
    <time_frame>baseline, week 4,12week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in lipid at Week 4, 8 and 12</measure>
    <time_frame>baseline, week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 4,8,12</measure>
    <time_frame>baseline, Week 4, 8,12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg SP2086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg SP2086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg SP2086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets(n=4),once daily for 84 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg SP2086</intervention_name>
    <description>Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days</description>
    <arm_group_label>50 mg SP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg SP2086</intervention_name>
    <description>Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days</description>
    <arm_group_label>100 mg SP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg SP2086</intervention_name>
    <description>Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days</description>
    <arm_group_label>200 mg SP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg Sitagliptin</intervention_name>
    <description>Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days</description>
    <arm_group_label>100 mg Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 Years to 70 Years ,Male and Female diagnosed with type 2 diabetes mellitus

          -  Patients not on an oral antihyperglycemic agent (OHA) with 7.0% ≤HbA1C ≤10.5%,or not
             on an OHA for 3 months with 7.0% ≤HbA1C ≤10.5%

          -  BMI 19~35 kg/m2

        Exclusion Criteria:

          -  Patient has history of type 1 diabetes mellitus

          -  Patient has history of ketoacidosis

          -  Patient has history of severe unconscious hypoglycemosis

          -  Patient has history of acute and chronic pancreatitis or pancreatic injury that may
             lead to high risk of pancreatitis

          -  Patient has history of decompensated heart failure (NYHA class III and IV), unstable
             angina, stroke or transient ischemic attack, myocardial infarction, persistence and
             clinical

          -  Patient has history of a history of hypertension, and after antihypertensive
             treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg

          -  Patient has severe liver or kidney disease,alanine aminotransferase &gt;2×UNL, Aspartate
             Aminotransferase &gt;2×upper normal limit(UNL)；total bilirubin &gt;2×UNL； creatinine&gt;1.5
             mg/dL (Male,132.6μmol/L) ，&gt;1.4 mg/dL(Female，123.8μmol/L)

          -  Patient has severe chronic gastrointestinal disease or therapy that may affect drug
             absorption, such as gastrointestinal surgery

          -  Patient has severe haematological diseases or other diseases leading to hemolyze and
             red blood cell unstable (malaria、haemolytic anaemia eg. )

          -  Patient has other endocrine diseases, for example
             hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on

          -  Patient has history of malignancy

          -  Patient has history of alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changyu Pan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sp2086</keyword>
  <keyword>Phase II</keyword>
  <keyword>monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

